Analyst Research

Report Title Price
Provider: New Constructs, LLC
Provider: S&P Capital IQ – STARS Reports
Provider: Pechala's Reports
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corporation acquires Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders

Thursday, 24 Apr 2014 07:30am EDT 

Celgene Corporation:Enters into global license agreement with Nogra Pharma Limited to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for treatment of moderate-to-severe Crohn's disease and other indications.Nogra Pharma Limited will receive upfront payment of $710 mln, regulatory, development and net sales milestone payments and tiered royalties.Aggregate payments for regulatory and development milestones could potentially be $815 mln for multiple indications. 

Company Quote

0.32 +0.34%
29 Aug 2014